CASI Pharmaceuticals, Inc (DE)
company.status.inactiveCIK 895051fmd_0YCVDDHDZJF2WQYHTNPR4YS3RAManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2010 to Dec 31, 2022, 51 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 15 | 30 | 43 |
| Rental revenue | – | – | – | – | – | – | – | 0 | 0 | – |
| Net interest income | 0 | (0) | (0) | (0) | 0 | 0 | 1 | 1 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | – | 0 | 4 | 10 | 13 | 16 |
| Gross profit | 0 | 0 | 0 | 0 | – | 0 | 0 | 6 | 18 | 27 |
| Research and development | 3 | 3 | 4 | 5 | 8 | 9 | 9 | 11 | 14 | 16 |
| Selling, general and administrative | – | – | – | – | – | 18 | 30 | 27 | 38 | 38 |
| Operating income | – | – | – | – | – | (27) | (47) | (53) | (42) | (34) |
| Interest expense | – | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | – | – | – | – | – | – | 0 | 1 | – |
| Income before taxes | – | (26) | – | (9) | (11) | (27) | (45) | (48) | (36) | (37) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Net income from continuing operations | – | (26) | – | (9) | (11) | (27) | (45) | (48) | (36) | (39) |
| Net income | (6) | (26) | (7) | (9) | (11) | (27) | (46) | (48) | (37) | (41) |
| Net income to common shareholders | (6) | – | – | – | – | – | – | – | – | – |